These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 30005109)
41. Basics of Sterile Compounding: Personnel Requirements for Sterile Compounding. Akers MJ Int J Pharm Compd; 2016; 20(4):307-314. PubMed ID: 28333676 [TBL] [Abstract][Full Text] [Related]
42. Description of outbreaks of health-care-associated infections related to compounding pharmacies, 2000-12. Staes C; Jacobs J; Mayer J; Allen J Am J Health Syst Pharm; 2013 Aug; 70(15):1301-12. PubMed ID: 23867487 [TBL] [Abstract][Full Text] [Related]
43. Basics of Sterile Compounding. Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 2. Martin M Int J Pharm Compd; 2018; 22(6):475-478. PubMed ID: 30384348 [TBL] [Abstract][Full Text] [Related]
44. Regulators faulted for inadequate compounding pharmacy oversight. Traynor K Am J Health Syst Pharm; 2013 Jan; 70(1):8-10. PubMed ID: 23261891 [No Abstract] [Full Text] [Related]
45. The role of outsourcing facilities in overcoming drug shortages. Mattingly AN J Am Pharm Assoc (2003); 2021; 61(1):e110-e114. PubMed ID: 32943335 [TBL] [Abstract][Full Text] [Related]
47. Compounded preparations in dermatology - analysis of prescribing habits in everyday clinical practice in Germany. Salzmann S; Salzmann M; Staubach P J Dtsch Dermatol Ges; 2020 Apr; 18(4):334-340. PubMed ID: 32247288 [TBL] [Abstract][Full Text] [Related]
48. Outsourced compounding can be problematic. Young D Am J Health Syst Pharm; 2002 Dec; 59(23):2261-2, 2264. PubMed ID: 12489360 [No Abstract] [Full Text] [Related]
49. ASHP guidelines on outsourcing sterile compounding services. Rinehart JR; Chan D; Cunningham M; Geller RE; Grandfield G; Heckman S; Kruzynski R; Nishizaki TT; Am J Health Syst Pharm; 2010 May; 67(9):757-65. PubMed ID: 20410553 [No Abstract] [Full Text] [Related]
50. Regulating compounding pharmacies after NECC. Outterson K N Engl J Med; 2012 Nov; 367(21):1969-72. PubMed ID: 23134357 [No Abstract] [Full Text] [Related]
51. Laboratory considerations of United States Pharmacopeia Chapter <71> sterility tests and its application to pharmaceutical compounding. Hyde TD Int J Pharm Compd; 2014; 18(1):46-52. PubMed ID: 24881341 [TBL] [Abstract][Full Text] [Related]
52. Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance. Greeson NM; Mixon W; Allan WC Int J Pharm Compd; 2020; 24(5):371-379. PubMed ID: 32886634 [TBL] [Abstract][Full Text] [Related]
53. [Analysis of compound prescriptions by practicing dermatologists. A study of 72,615 prescriptions for patients insured by the North Rhine-Westphalia BKK]. Altmeyer P; Bergmeyer V; Wienand W Hautarzt; 1997 Jan; 48(1):12-20. PubMed ID: 9132381 [TBL] [Abstract][Full Text] [Related]